Compare · HSDT vs SLNO
HSDT vs SLNO
Side-by-side comparison of Solana Company (HSDT) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HSDT and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 34.3x HSDT ($80.6M).
- Over the past year, HSDT is down 96.7% and SLNO is down 31.8% - SLNO leads by 64.9 points.
- SLNO has been more active in the news (39 items in the past 4 weeks vs 14 for HSDT).
- SLNO has more recent analyst coverage (12 ratings vs 3 for HSDT).
- Company
- Solana Company
- Soleno Therapeutics Inc.
- Price
- $1.38+9.52%
- $53.02+0.08%
- Market cap
- $80.6M
- $2.76B
- 1M return
- -36.11%
- +0.76%
- 1Y return
- -96.71%
- -31.78%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 14
- 39
- Recent ratings
- 3
- 12
Solana Company
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest HSDT
- Director Jiang Cosmo Yi exercised 1,005,040 shares at a strike of $0.00 and covered exercise/tax liability with 610 shares (SEC Form 4)
- SEC Form 4 filed by Director Jiang Cosmo Yi
- Solana Company filed SEC Form 8-K: Entry into a Material Definitive Agreement
- SEC Form 424B5 filed by Solana Company
- SEC Form SD filed by Solana Company
- Director Straw Edward M was granted 6,360 shares, increasing direct ownership by 291% to 8,542 units (SEC Form 4)
- Director Mello Sergio was granted 6,360 shares (SEC Form 4)
- Director Lee Michel Kai Tai was granted 6,360 shares (SEC Form 4)
- Director Walter Blane was granted 6,360 shares, increasing direct ownership by 291% to 8,542 units (SEC Form 4)
- Amendment: Director Straw Edward M was granted 2,180 shares, increasing direct ownership by 109,000% to 2,182 units (SEC Form 4)
Latest SLNO
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Manning Meredith returned 64,507 shares to the company, closing all direct ownership in the company (SEC Form 4)